Journal of Clinical and Investigative Dermatology
Research Article
Sequencing of within-Subject Primary and Metastatic Cutaneous Squamous Cell Carcinomas Reveals Novel Diagnostic and Therapeutic Targets for Metastatic Disease
Maggie Chow1, Sarah Murray2, Adam Miller3, Rachel Chang3, Brian Hinds3, Bryan Sun3, Shang I Brian Jiang3*
1Department of Dermatology, Keck Medical Center of the University of
Southern California, USA
2Department of Pathology, University of California, San Diego, USA
3Department of Dermatology University of California, San Diego, USA
*Address for Correspondence:
Shang I. Brian Jiang, Department of Dermatology, University of
California, San Diego, Mohs Surgery and Dermatologic Oncology
Fellowship 8899 University Center Lane Ste 350 San Diego CA
92122, USA Email: S2jiang@ucsd.edu
Submission: 03 November, 2022
Accepted: 05 December, 2022
Published: 09 December, 2022
Copyright: © 2022 Chow M, et al. This is an open access article
distributed under the Creative Commons Attri-bution License,
which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Abstract
Cutaneous squamous cell carcinoma (cSCC) is a common type of
skin cancer that rarely metastasizes. However, metastasis is associated
with significant morbidity and mortality. Thus, additional study on the
molecular markers that prognosticate aggressive behavior of cSCC
are needed to improve diagnostic and therapeutic tools. Our goal
was to identify genetic mutations in cSCCs that may be markers of
or contribute to metastatic risk. A matched case-control study of high
depth sequencing of 397 genes in matched metastatic and primary
cSCC from 12 patients was performed in 2020. A follow up of at
least 5 years was required for all patients. Identified mutations were
compared between the two groups. Over 1,000 deleterious mutations
were identified in metastatic and primary cSCC samples, of which TP53,
LRP1B and FAT1 mutations were most common overall. In comparing
between the metastatic and primary cSCCs, 53 genes were unique
to the metastatic group. Mutations in SETBP1, AR, and TSHR were most
common and unique to the metastatic samples. Though also found in
primary cSCC, NOTCH1 was significantly more commonly mutated in
metastatic samples than primary cSCC.We nominate several genes
that, when mutated, serve as markers for more aggressive behavior
in cSCCs. Further investigations into this complex but important topic
are needed.